Target therapies for MYCN-positive tumors

Biogenera deals with research and development of new targeted molecular therapies, designed to treat incurable tumors. The company was founded in 2008 to develop new biotechnological drugs, which have obtained orphan drug designation from the EMA, for the treatment of the three main types of pediatric cancer (the leading cause of death in industrialized countries in the age group 0-15 years).

IAG Champions of the investment in Biogenera: Enrico Chiapparoli e Elisabeth Robinson

Date of investment January, 2013

Offices Ozzano dell’Emilia, Italy

Life Science